Skip to main content
. Author manuscript; available in PMC: 2012 Sep 29.
Published in final edited form as: Nature. 2012 Mar 28;483(7391):570–575. doi: 10.1038/nature11005

Figure 1. A systematic screen in cancer cell lines identifies therapeutic biomarkers.

Figure 1

a, The number of tumour-derived cell lines used for screening classified according to tissue type (n = 639 in total). b, The panel of 130 screening drugs classified according to their therapeutic targets, primary effector pathways, and cellular functions. A single drug may be included in multiple categories. The inset indicates the number of drugs screened against a selection of prototype cancer targets. c, A volcano plot representation of MANOVA results showing the magnitude (effect; x-axis) and significance (p-value; inverted y-axis) of all drug-gene associations. Each circle represents a single drug-gene interaction and the size is proportional to the number of mutant cell lines screened (range 1 – 334). The horizontal dashed line indicates the threshold of statistical significance (0.2 FDR, P < 0.0099). Insets I and II are magnified views of selected highly significant associations and the drug name, therapeutically relevant target(s) (in superscript), and cancer gene (in brackets) are given for each. The p-values for nilotinibABL(BCR-ABL), P = 2.54 × 10−65, and nutlin-3aMDM2(TP53), P= 2.78 × 10−37, have been capped at 1 × 10−28 in this representation.